Overview

Efficacy and Safety of RC28-E Versus Aflibercept

Status:
Recruiting
Trial end date:
2025-12-29
Target enrollment:
Participant gender:
Summary
This is a randomized, double-masked, multicenter study comparing the the efficacy and safety of RC28-E injection (a chimric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) versus aflibercept in patients with wet age-related macular degeneration.
Phase:
Phase 3
Details
Lead Sponsor:
RemeGen Co., Ltd.
Treatments:
Aflibercept